Chemically Modified Antisense Oligonucleotides for Specific RNA Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing RNA editing methods require genetically modified cells or delivery of recombinant enzymes, leading to inefficiencies and challenges in therapeutic applications, particularly in multicellular organisms like humans, due to issues such as promiscuous editing and the need for specific delivery mechanisms.
Innovation Solution
Development of chemically modified single-stranded antisense oligonucleotides that form a double-stranded complex with target RNA, utilizing endogenous ADAR enzymes for specific adenosine deamination without requiring additional modifications or recombinant proteins, by employing a Central Triplet with specific sugar and base modifications and mismatches to enhance stability and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetically modified cells or recombinant enzymes are used for RNA editing, then RNA editing capability is achieved, but delivery complexity and promiscuous editing increase
Solution Approach 1:
The patent extracts the essential catalytic domain of ADAR enzymes and combines it with a simplified guide RNA system, removing the need for complex recombinant protein delivery while retaining RNA editing capability. The deaminase domain is engineered to function with short guide RNAs, eliminating dependence on full-length recombinant enzymes.
Solution Approach 2:
The patent introduces a simplified guide RNA as an intermediary that directs the engineered deaminase domain to specific target sites. This guide RNA mediates between the editing enzyme and target RNA, providing specificity without requiring complex delivery mechanisms or genetically modified cells.
2Ease of operation
If endogenous ADAR enzymes are utilized, then delivery simplicity is improved, but editing specificity decreases due to promiscuous editing
Solution Approach 1:
The patent applies local quality by designing the guide RNA with specific structural features (stem-loop configuration, mismatch positions) that create a localized recognition pattern. This local structural quality ensures that endogenous ADAR enzymes are directed to specific target sites while avoiding promiscuous editing at non-target locations.
Solution Approach 2:
The patent changes key parameters of the guide RNA system, including its length (shorter than natural substrates), secondary structure (stem-loop with specific mismatches), and sequence composition. These parameter changes transform the interaction with endogenous ADAR enzymes from promiscuous to highly specific.
3Reliability
If chemically modified oligonucleotides are used, then stability and specificity are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies chemical modifications to the guide RNA at specific positions (2'-O-methyl, phosphorothioate linkages) to enhance stability and specificity. These targeted parameter changes at critical locations provide maximum benefit while minimizing synthesis complexity compared to full modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for targeted and efficient RNA editing in mammalian cells, including therapeutic applications for genetic disorders, by utilizing natural ADAR enzymes, reducing promiscuous editing and enhancing stability, thereby improving treatment efficacy.
Implementation Method 1
forming a double stranded complex with a target RNA sequence
Implementation Method 2
for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell
Data Source
AI summary
The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a cukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolceular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.